Literature DB >> 8302456

Characterization of a non-Goodpasture autoantibody to type IV collagen.

C Johansson1, R Butkowski, P Swedenborg, P Alm, J Wieslander.   

Abstract

Goodpasture's syndrome is a very severe and aggressive autoimmune kidney disease. The patients' autoantibodies, which are pathogenic, are restricted to the C-terminal region of the alpha 3-chain of type IV collagen. In this paper we characterize an anti-type IV collagen antibody from a patient with a non-progressive form of glomerulonephritis. ELISA and immunoblotting were used to study the specificity of this patient's antibodies. The patient had high titres of antibodies restricted to the C-terminal region of the alpha 1-chain of type IV collagen. The antibody recognized an epitope hidden in the NC1 molecule which was fully exposed after denaturation or reduction. It was an IgG3 antibody composed of only lambda light chains, indicating that it has a potential to induce inflammatory damage and that it is probably monoclonal. This patient also had MPO-ANCA which were of IgG1 subclass. Our patient had no disease progression during the 5 years of treatment. Even though the anti-alpha 1 (IV) antibodies react with the same domain, but of a different chain of type IV collagen compared to the Goodpasture's antibodies, they do not induce any severe damage. It is thus uncertain if the anti-alpha 1 (IV) antibodies have any pathogenic role; the kidney damage might have been caused by the MPO-ANCA. The findings support the theory that the anti-alpha 3 (IV) antibody causes disease in Goodpasture's syndrome and that antibodies restricted to other subunits of the C-terminal region of type IV collagen are less harmful.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8302456

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  1 in total

Review 1.  Advances in human antiglomerular basement membrane disease.

Authors:  Zhao Cui; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.